Premarin Tablet, Film Coated
NDC Package 0046-1102-52
Package Information
Premarin (estrogens, conjugated) tablets is pREMARIN therapy is contraindicated in individuals with any of the following conditions: •Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)]•Breast cancer or a history of breast cancer except in appropriately selected patients being treated for metastatic disease [see Warnings and Precautions (5.2)]•Estrogen-dependent neoplasia [see Warnings and Precautions (5.2)]•Active DVT, PE, or a history of these conditions [see Warnings and Precautions (5.1)]•Active arterial thromboembolic disease (for example stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1)]•Known anaphylactic reaction or angioedema with PREMARIN [see Warnings and Precautions (5.7, 5.15)]•Hepatic impairment or disease [see Warnings and Precautions (5.11)]•Protein C, protein S or antithrombin deficiency, or other known thrombophilic disorders. This formulation utilizes a tablet, film coated delivery system. Marketed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., this product is identified by NDC 0046-1102 and is authorized under FDA application NDA004782.
Identification & Billing
- RxCUI: 150840 - PREMARIN 0.625 MG Oral Tablet
- RxCUI: 150840 - estrogens, conjugated (USP) 0.625 MG Oral Tablet [Premarin]
- RxCUI: 150840 - Premarin 0.625 MG Oral Tablet
- RxCUI: 197660 - estrogens, conjugated 0.3 MG Oral Tablet
- RxCUI: 197660 - estrogens, conjugated (USP) 0.3 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0046 - Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.
- 0046-1102 - Premarin
- 0046-1102-52 - 1 BLISTER PACK in 1 CARTON / 5 TABLET, FILM COATED in 1 BLISTER PACK
- 0046-1102 - Premarin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0046-1102). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0046-1102-52 identifies a specific commercial package of 1 blister pack in 1 carton / 5 tablet, film coated in 1 blister pack of Premarin, a human prescription drug labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. This tablet, film coated is formulated for oral use and contains estrogens, conjugated as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. on January 01, 2006. The current certification is valid through December 31, 2027.
How is this Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00046110252. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.